Treatment Experienced People Living With HIV switching to DOR/3TC/TDF in Outpatient Setting: Real-World Data on Tolerability and Cost Savings From an Italian Multicenter Cohort

J Acquir Immune Defic Syndr. 2024 Jun 1;96(2):e10-e11. doi: 10.1097/QAI.0000000000003427.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Anti-HIV Agents* / economics
  • Anti-HIV Agents* / therapeutic use
  • Cohort Studies
  • Cost Savings
  • Female
  • HIV Infections* / drug therapy
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Outpatients
  • Tenofovir / therapeutic use